DiPT
| Clinical data | |
|---|---|
| Pronunciation | /ˌdaɪˌaɪsoʊˌproʊpɪlˈtrɪptəmiːn/ |
| Other names | Diisopropyltryptamine; N,N-Diisopropyltryptamine; DiPT; DIPT; Dipt; Dipsy |
| Routes of administration | Oral, smoking |
| Drug class | Serotonin receptor agonist; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Onset of action | Oral: 20 minutes–1 hour Smoking: 4–8 minutes |
| Duration of action | 4–8 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C16H24N2 |
| Molar mass | 244.382 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Diisopropyltryptamine (DiPT), also known as N,N-diisopropyltryptamine, is a psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It is unusual among psychedelics in that at usual doses it primarily or exclusively produces strong auditory changes, including decreased pitch, harmonic distortion, and sound unfamiliarity, but produces no other hallucinogenic effects such as visuals. However, the drug may produce more classically psychedelic effects at very high doses. It is taken orally, but can also be smoked.
The drug acts as a serotonin receptor agonist, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. It has weak activity at the serotonin 5-HT1A receptor. DiPT does not appear to bind to the serotonin 5-HT6 receptor or to several other serotonin receptors. It produces psychedelic-like effects in animals, which appear to be mediated primarily by serotonin 5-HT2A receptor activation. The mechanisms by which DiPT produces selective auditory changes are unknown. Derivatives of DiPT include 4-HO-DiPT (iprocin) and 5-MeO-DiPT (foxy methoxy), among others.
DiPT was first described in the scientific literature by 1959. The basic properties of DiPT in humans were described by Alexander Shulgin in 1976 and its effects were described in detail by Shulgin in subsequent publications in the 1980s and in his 1997 book TiHKAL (Tryptamines I Have Known and Loved). DiPT was encountered as a novel designer drug in 2005. However, it appears to be little-used recreationally compared to other psychedelic drugs, perhaps due to its unusual effects.